Skip to main content

RTW Investments, LP's Form 4 filing

Rocket Pharmaceuticals, Inc. (RCKT) · filed Oct 11, 2022

Accession no.
0000902664-22-004508
Filed
Oct 11, 2022, 4:31 PM ET
Trade date
Oct 6, 2022
Filing delay
5 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 1 non-derivative transaction. Open-market purchases total $20.0M. It was filed 5 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
RTW Investments, LPCIK 0001493215Director, 10% Owner, Other: See Remarks
Wong RoderickCIK 0001493280Director, 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 6, 2022Common Stock, $0.01 par value ("Common Stock")PPurchaseAcquired+1,355,932$14.75+$19,999,99717,628,567Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Remarks

The Adviser may be deemed to be a director by deputization for purposes of Section 16 under the Securities Exchange Act of 1934 by virtue of the fact that each of Dr. Wong and Naveen Yalamanchi, M.D., who serves as a Partner and Portfolio Manager of the Adviser, currently serve on the board of directors of the Issuer. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Read the full filing on SEC EDGAR (opens in a new tab)